Exosomes are tiny membrane-bound packages that cells release to communicate with each other, carrying proteins, lipids and small RNA. The biology is well documented. What is far less settled is whether a particular commercial product produces a particular clinical result in a particular person.
Where the evidence is strongest. Applying an exosome-containing preparation immediately after a procedure that creates controlled micro-injury — fractional laser, radiofrequency microneedling — has a plausible rationale, because the skin barrier is temporarily open and the healing phase is when signalling molecules would matter. Reported benefits are mostly about recovery: less redness, less swelling, shorter downtime. That is a modest and credible claim.
Where it is not. As of 2026 no exosome product holds approval as a biologic from the FDA, EMA, MHRA or TGA, and the US FDA has issued public safety warnings about unapproved exosome products. The clinical evidence for injected exosomes in aesthetics is early, small-scale and largely industry-funded. Regulatory positions differ by country and are changing, but the underlying fact travels.
What to ask. Which product and which manufacturer. Whether it is being applied topically after a procedure or injected — that answer changes both the evidence base and the regulatory picture. What the realistic expectation is, over how many sessions, and what happens if nothing changes. And what the established alternative is, because for most concerns exosomes are marketed for there is one with better evidence behind it.
For melasma in particular, get assessed first. It is a chronic relapsing condition with proven treatments and a strong tendency to rebound, and starting with something novel rather than something established is how people spend a lot and improve little.